Dometa

There is no image.

Domperidone

Method of action: Antiemetic, Drugs For Functional Gastrointestinal Disorders

Treatment option: Pain, Heartburn, Flatulence, Belching, Oral Cavity, Burping, Reflux, Morning Sickness, Esophagitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dometa

Dometa is a medicine containing the active substance Domperidone, which is classified as a Prokinetic Anti-emetic and a Dopamine Antagonist. This synthetic organic compound is fundamentally used to provide relief from acute sickness and upper gastrointestinal discomfort.

Quick Facts

Property	Description
Active Ingredient	Domperidone
Common Forms	Tablets, Oral Suspension, Suppositories
Pharmacological Class	Prokinetic Anti-emetic
General Purpose	Relief from nausea and vomiting
Origin	Synthetic organic compound

What Type of Medicine is Dometa (Domperidone)?

Domperidone belongs to the Prokinetic Anti-emetic pharmacological class, a category focused on its effects on gastrointestinal motility. It functions as a Dopamine Antagonist by blocking specific chemical messengers (dopamine receptors) primarily located in the periphery and the area of the brain responsible for triggering vomiting, known as the chemoreceptor trigger zone (CTZ). The antiemetic mechanism involves antagonism of D2 and D3 dopamine receptors. This peripheral selectivity is a key feature, distinguishing it from less targeted dopamine antagonists by limiting passage into the central nervous system, focusing its effect on the digestive tract and the signals responsible for nausea.

Composition, Origin, and Available Forms

The product is a single-ingredient preparation whose sole therapeutic agent is Domperidone (C22H24ClN5O2), a complex substance synthesized chemically. Dometa is supplied in multiple dosage forms to accommodate various patient needs and administration preferences. These forms, which include various types of oral tablets (such as film-coated or orodispersible forms), oral suspension, oral drops, and suppositories, make the medicine suitable for both oral and rectal routes of administration. The availability of oral drops, for example, allows for flexible use in patient groups who struggle to swallow solid forms.

General Purpose: Anti-Sickness and Motility Relief

The general purpose of Domperidone is to address both the subjective feeling of sickness and the underlying physical cause when related to slowed digestion. Its dual capacity allows it to speed gastrointestinal peristalsis (muscle contractions) and enhance motility in the upper digestive tract while simultaneously suppressing the signals that cause nausea and vomiting. Its therapeutic role includes the symptomatic treatment of nausea and vomiting. This dual function effectively provides relief from discomfort associated with certain gastrointestinal motility disorders by helping the stomach empty more efficiently.

Regulatory References

EMA Domperidone Referral/Review

What side effects are possible with Dometa?

Possible Side Effects and Safety Information

The safety profile of Dometa (Domperidone) is formally defined by official government regulatory authorities, outlining both common and rare adverse reactions and specific usage constraints.

Adverse reactions are classified by frequency, with Common effects (affecting up to 1 in 10 people) including dry mouth. Uncommon effects (up to 1 in 100 people) may involve anxiety, dizziness, diarrhea, rash, or somnolence. Other documented effects are grouped by system, such as Endocrine disorders (e.g., galactorrhea, breast tenderness) and Nervous system disorders (e.g., headache).

Serious Adverse Reactions and Cardiac Risk

Official regulatory documents emphasize the potential for serious cardiac adverse reactions, which are classified as Very Rare. These include QTc interval prolongation, ventricular arrhythmias (Torsades de Pointes), and Sudden Cardiac Death (SCD). The risk of these events is explicitly stated as being higher in patients taking higher daily doses and with longer durations of treatment.

Safety-Related Restrictions

Safety statements stipulate that the medicine is contraindicated in specific high-risk situations. These include patients with moderate or severe hepatic impairment, known existing prolongation of cardiac conduction intervals, and underlying cardiac diseases such as congestive heart failure. Dometa is also contraindicated when co-administered with other QTc-prolonging medicines or potent CYP3A4 inhibitors.

Overdose and Emergency Response

Overdose and when to seek help

Feature	Official Regulatory Statement
Documented overdose presentations:	Symptoms include Central Nervous System (CNS) effects such as somnolence, altered consciousness, and disorientation. Convulsion, agitation, and extrapyramidal reactions (abnormal involuntary movements) are also documented.
Physiological systems affected:	The cardiovascular system is affected, with the possibility of serious risks including QT interval prolongation, ventricular arrhythmias, Torsades de pointes, and sudden cardiac death. The nervous system is also affected.
Emergency-response statements:	Standard symptomatic treatment should be administered immediately. Management may include gastric lavage (within one hour) and activated charcoal. Anticholinergics may be used for extrapyramidal reactions. No specific antidote is known.
When immediate medical help is required:	Individuals must seek immediate medical attention for suspected overdosage. Electrocardiogram (ECG) monitoring is required due to the risk of cardiac effects. Patients should promptly report any cardiac symptoms.

Population-specific notes: Overdose cases have been reported primarily in infants and children.

Connection to the overall overdose profile: Regulatory documents define the Domperidone overdose profile by noting the critical dual risk of severe CNS depression and potentially fatal cardiac events. Due to the high cardiotoxicity risk and the lack of a specific antidote, regulatory bodies mandate that immediate medical help be sought, coupled with the essential procedural requirement of continuous ECG monitoring in a hospital setting.

Therapeutic Uses of Dometa

Dometa: Main Uses and Therapeutic Benefits

Quick Facts: What Dometa Treats
Primary Indication: Symptomatic management of nausea and vomiting.
Targeted Relief: Upper abdominal discomfort and a sense of fullness (epigastric sense of fullness).
Action: Facilitates relief of symptoms associated with delayed movement of the stomach (gastrointestinal motility).

Dometa is authorized for the symptomatic relief of nausea and vomiting in adults and adolescents weighing 35 kg or more. Its primary benefit is providing relief from these acute symptoms. The medication also addresses certain symptoms associated with delayed gastric emptying or motility disorders of the upper gastrointestinal tract.

For adult patients, additional uses may include the management of a feeling of epigastric sense of fullness (feeling full after small amounts of food), upper abdominal discomfort, and regurgitation of gastric contents. By influencing the movement and contractions of the stomach and small intestine, Dometa helps to facilitate the correct passage of contents through the digestive system. Use is generally restricted to the lowest effective dosage for the shortest duration necessary, typically not exceeding one week for acute symptoms.

Eligibility and Restrictions for Use

Official Population Eligibility for Dometa

Dometa is officially authorized for use in Adults and Adolescents who are 12 years of age or older and weigh 35 kg or more. Use is generally no longer licensed for children under 12 years or adolescents below 35 kg because efficacy has not been established in these younger groups.

Absolute Contraindications

Use of Dometa is absolutely contraindicated in several populations as defined by regulatory bodies. These include patients with:

Moderate or Severe Hepatic Impairment (liver disease).
Specific Cardiac Conditions such as pre-existing QTc prolongation, Congestive Heart Failure, or significant electrolyte disturbances (e.g., Hypokalaemia).
Conditions where stimulating gut motility could be harmful, such as gastrointestinal haemorrhage, mechanical obstruction, or perforation.
Prolactin-releasing pituitary tumours (Prolactinoma) or known hypersensitivity to the substance.

Restricted Use and Caution

The drug is subject to specific restrictions for other populations:

Older Adults (over 60 years) should use the medicine with Caution due to a documented higher cardiac risk.
Use is not recommended during Breastfeeding due to excretion into human milk.
Patients with Severe Renal Impairment require reduction of dosing frequency and regular treatment review.
The medicine is contraindicated if co-administered with QT-prolonging medicines or potent CYP3A4 inhibitors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory authorities classify the potential for drug interactions with Domperidone (Dometa) into two critical areas: pharmacokinetic inhibition and pharmacodynamic effects on the heart.

Co-administration with specific medicinal products is formally contraindicated due to these risks. This prohibition includes all known QT-prolonging medicinal products to prevent an additive effect on the QTc interval, which increases the risk of ventricular arrhythmias. It also includes all potent CYP3A4 inhibitors (such as certain systemic azole antifungals and macrolide antibiotics), which significantly reduce Domperidone’s clearance and lead to a multi-fold increase in plasma exposure.

Interaction Type	Examples of Interacting Agents
Pharmacokinetic (CYP3A4 Inhibition)	Potent CYP3A4 Inhibitors, Grapefruit juice
Pharmacodynamic (Cardiac Risk)	QT-prolonging agents, conditions causing bradycardia

Absorption-modifying interactions are also documented. The absorption of Domperidone is delayed when taken after a meal, and its bioavailability is reduced when taken simultaneously with antacids or antisecretory agents. Consequently, official labeling requires timing separation from these products. The interaction risk is also noted to be higher in specific populations, including patients over 60 years and those with moderate or severe hepatic impairment, where the medicine is strictly contraindicated due to prolonged clearance.

Mechanism of Action

Dometa selectively binds to the Sclerostin Receptor (SOST-R) located on the surface of osteocytes, thereby preventing the binding and action of the endogenous protein sclerostin. This interaction classifies Dometa as a selective sclerostin antagonist.

Inhibition of sclerostin leads to an upstream activation of the Wnt/beta-catenin signaling pathway within the bone microenvironment. Activation of the Wnt pathway promotes the differentiation of mesenchymal stem cells into osteoblasts. The resulting cascade is characterized by a dual physiological effect: increased osteoblastogenesis (new bone formation) and a simultaneous reduction in osteoclast-mediated bone resorption. This pathway modulation ultimately increases the expression of bone matrix proteins. The mechanism is confined to altering cellular processes and signaling pathways related to bone remodeling.

Dosage and Administration Information

How to Use Dometa

Dometa (Domperidone) is a Prokinetic Anti-emetic that is used based on specific administration protocols.

Official Administration Guidelines

Feature	Guideline
Route of Administration	The medicine is used for Oral (tablets, suspension/drops) and Rectal (suppositories) administration.
Standard Dosing (Adults 35 kg)	The dosage is 10 mg per administration. The maximum daily dose is 30 mg, regardless of the route of administration.
Frequency and Timing	The medicine is taken up to three times daily (t.i.d.) with doses spaced approximately 8 hours apart.
Administration Context	Oral forms must be taken 15–30 minutes before meals (preprandially) for optimal absorption.

Use Patterns and Procedural Constraints

The usage of Dometa is restricted to the lowest effective dose for the shortest duration possible. Treatment for acute symptoms typically does not exceed seven days.

Special Conditions:

Administration is restricted to adolescents 12 years of age and older who weigh 35 kg or more. For patients with severe renal impairment, the dosing frequency is typically reduced to once or twice daily due to potential changes in drug elimination.

If a scheduled dose is missed, the missed dose is omitted if the next dose is due shortly. The dose is not doubled to compensate for the missed administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dometa

Evidence for Symptomatic Relief of Acute Nausea and Vomiting

Research exploring short-term changes in symptoms has focused on Domperidone as an agent studied for the relief of acute nausea and vomiting. The primary research consists of Randomized Controlled Trials (RCTs), where participants were often assigned by chance to receive either Domperidone or an inactive substance (placebo). These findings were later summarized in systematic reviews that contributed to the evidence used in regulatory review.

Studies examined outcomes related to episodic or acute changes in physical discomfort. Researchers measured symptom intensity or variability by tracking vomiting episodes or changes in nausea severity over short time intervals. Findings describe patterns observed in studies of adults and adolescents. Regulatory limits on the approved use of the medicine focus on the shortest duration necessary, generally not exceeding seven days.

Evidence for Symptoms Associated with Upper Gastrointestinal Motility

Domperidone was evaluated in research contexts involving fluctuating or unstable symptoms related to the movement of the stomach and upper intestine. Studies explored its use in conditions marked by functional limitations, such as chronic delayed gastric emptying (gastroparesis) and functional dyspepsia, which may present with symptoms like upper abdominal discomfort or a persistent feeling of fullness.

Findings indicate patterns where studies report how symptoms evolved in the observed populations during the study period. However, findings were mixed across the full range of previous, broader indications. Data for long-term use in these chronic conditions are still emerging. Long-term outcomes are not fully established when the medicine is used for longer durations.

Evidence Gaps and Remaining Research Uncertainties

The current body of evidence has several limitations that regulatory bodies have addressed. A major limitation is that follow-up durations were limited, restricting the understanding of outcomes related to physical discomfort over time. Furthermore, scientific literature notes limited or insufficient comparative evidence examining Domperidone against a comprehensive range of other available medicines for certain indications. The evidence contributes to the broader evidence landscape but highlights that the authorized use of Domperidone remains restricted to specific, short-term symptom relief indications.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dometa (FAQ)

Q: Does Dometa need to be taken consistently to work, or is it only for symptoms?

Official guidance states that Dometa is indicated for the relief of symptoms, specifically nausea and vomiting. Regulatory guidelines describe that the medicine should be used at the lowest effective dose, with the shortest duration necessary, which is generally not intended to exceed one week for acute symptoms.

Q: Is Dometa associated with any long-term health risks?

Official safety reviews describe a small increased risk of serious cardiac adverse reactions, such as ventricular arrhythmias and sudden cardiac death. Regulatory documents note that this risk is thought to be higher when the medicine is used for longer durations of treatment or at higher doses. Due to these safety concerns, authorized use of the medicine is generally restricted to short courses.

Q: How does Dometa differ from other medicines that treat similar conditions?

Dometa is classified as a peripheral dopamine receptor antagonist. This means its mechanism of action is primarily focused on the digestive tract and the part of the brain that triggers vomiting, with restricted passage into the central nervous system. This peripheral selectivity is a key feature that distinguishes its mechanism.

Q: How quickly should I expect to see an effect after starting Dometa?

When the medicine is taken on an empty stomach, the maximum concentration in the blood (peak plasma level) is reached quickly, typically within about 30 minutes. The symptomatic effect is described in relation to this peak concentration.

Q: What is the total duration of time Dometa is active in the body?

According to pharmacokinetics data, the elimination half-life of Dometa is approximately 7.0 hours in healthy individuals. The half-life refers to the time it takes for the plasma concentration of the medicine to be reduced by half.

Q: What is the information available about Dometa use during pregnancy?

Regulatory agencies note that there is limited data available on the use of this medicine in pregnant women. Official product information advises that the use of Dometa during pregnancy is only recommended when the expected therapeutic benefit to the mother is judged to outweigh the potential risks to the fetus.

Q: What are the official sources for patient information about Dometa?

Official and verified patient information is published by national regulatory agencies. These documents include the Summary of Product Characteristics (SmPC), the Patient Information Leaflet (PIL), or the Product Monograph, which contain the facts used by healthcare professionals and patients.

Q: Why do official documents warn against using Dometa with alcohol?

Official patient guides include a recommendation to avoid alcohol because it may intensify documented side effects, such as feeling sleepy or experiencing an irregular heartbeat.

Q: Is it normal to feel no immediate effect after taking the first Dometa dose?

Feeling no immediate effect is considered normal. The time it takes for the medicine to reach its maximum concentration in the bloodstream is around 30 minutes, indicating a typical delay before the maximum expected symptomatic relief.

Q: Are there any specific lifestyle changes that are discussed in relation to Dometa use?

Official documentation includes a specific statement advising against consuming grapefruit juice while taking this medicine. Grapefruit juice is known to increase the level of Dometa in the bloodstream and may subsequently increase the potential for adverse effects.

Q: Is Dometa classified as a controlled substance in the US or other countries?

Official scheduling information indicates that Dometa is not classified as a controlled substance by US authorities. While it is widely available in many countries, it is not approved for general prescription use in the United States.

Q: What are the first steps to take if I suspect a severe side effect from Dometa?

If heart-related symptoms such as a sudden irregular heartbeat, chest tightness, or fainting are experienced, official patient advisories state that immediate medical attention should be sought. The reporting of all suspected adverse reactions to a healthcare professional or a national monitoring system is advised.

Q: Is there a generic version of Dometa available?

Yes, the active ingredient, Domperidone, has been available globally for an extended period of time. As a result, authorized generic versions of the medicine are widely available for prescription in jurisdictions where it is approved for sale.

Q: What are the requirements for monitoring (like blood tests) while on Dometa?

For patients receiving long-term treatment or those identified as being at higher cardiac risk, official safety guidelines describe that regular review by a healthcare provider is necessary for these patients. In some jurisdictions, this monitoring may include requesting an electrocardiogram (ECG) to check heart rhythm.

Q: What happens to Dometa in the body after it has been used?

The processes of breakdown and elimination begin after Dometa has been taken, primarily in the liver through metabolism. The resulting compounds are then eliminated from the body mostly through the feces (about 66%) and the urine (about 31%).

Q: What is the risk of stopping Dometa suddenly, according to official warnings?

While not universally highlighted, post-market vigilance reports have described occurrences of temporary withdrawal symptoms upon abruptly stopping the medicine, particularly after long-term use or at higher doses. These symptoms can include anxiety, insomnia, or heart rate changes.

How should Dometa be stored and disposed of?

Dometa must be stored strictly according to the conditions defined in the official product labeling to maintain its stability and quality.

Storage Requirements

Regulatory documents specify that Dometa must be stored at controlled room temperature, typically between 15 C and 30 C and not exceeding 30 C.

Do not refrigerate or freeze the medicine.
It must be protected from light and moisture and kept in its original, tightly closed package.
The product must always be stored out of the sight and reach of children.

Disposal Instructions

Official disposal rules advise that unused or expired Dometa must not be thrown away in the household trash or disposed of via wastewater (flushed down a toilet or sink). Patients should consult a pharmacist or use an approved pharmacy take-back program for proper pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Indonesia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z